Invibio Aims to Accelerate Time-to-Market for Innovative Medical Devices

Company investing in plans to streamline device development

Invibio Biomaterial Solutions has implemented a series of investments that it hopes will deliver demonstrable clinical outcomes, lower healthcare costs and shorter development time for innovative concepts.

Background

As a leader in the use of PEEK-OPTIMA polymer solutions in medical applications, Invibio claims to deliver clinical and economic benefits in Dental, Spine, Orthopedics, and Trauma. From that standpoint the company is now embarking on a quest to help medical device companies accelerating the time-to-market of new innovations by changing the way they develop new products.

At the heart of the programme, the company has invested in clinical-study expertise, component manufacturing facilities and component testing. The innovator of implantable PEEK-OPTIMA™ polymer is also launching a new website that efficiently provides information on materials and applications to OEMs and Health Care Professionals (HCPs), and a comprehensive journal with further scientific information and clinical evidence.

Invibio argues that defining “best clinical outcomes” while delivering healthcare at the lowest possible cost is challenging. It says clinical outcomes are typically obtained through expensive, time-comsuming clinical studies.  Add to this inherent variations in the level of clinical evidence and the industry faces a difficult task, when seeking to demonstrate that new product innovations are addressing these issues and, ultimately, improving patient care.

So the answer they’re proposing is a raft of tools that seek to redefine the total cost of care. Invibio recently recruited a clinical study manager and is working with Health Care Professionals (HCPs), medical device manufacturers and other stakeholders to determine the clinical and economic impact of its solutions. In addition, the company has made it easier for medical device companies to innovate and change the way they develop new products by investing in new component manufacturing facilities and component testing. This delivers greater role in the design, development and commercialization of trauma fracture plates made of PEEK-OPTIMA™ Ultra Reinforced, a carbon-fiber-reinforced polymer.

Invibio´s new website will serve as a hub for OEMs and Health Care Professionals (HCPs) alike. For OEMs, it is a go-to practical and educational resource for implantable PEEK related knowledge and clinical data, including product offerings, manufacturing, quality and partnering for custom-design and regulatory services. For HCPs, it aims to facilitate the clinical adoption of new medical devices made of the company´s high performance polymer, by providing implantable PEEK-related knowledge, clinical data and information concerning the potential benefits of Invibio´s solutions for HCPs and ultimately their patients.

With a new emphasis on clinical evidence and an easy to navigate online academy, Invibio says it is not only addressing the needs of different target groups, but also hoping to contribute to achieving the best possible clinical outcomes and lowering the total costs of care.

Company comments

John Devine, Medical Business Director at Invibio Biomaterial Solutions explains the quandary of innovative medical device makers: “When faced with delivering a consistent, quality of healthcare at the lowest cost, the market has yet to create an environment that encourages more ambitious solutions than simply preserving the status quo at a fractionally reduced price.”

“The majority of current cost metrics focus on up-front purchasing costs rather than the total cost of care. For example, no standards exist for accurately assessing complication rates, or measuring the cost of revision surgeries, and reflecting these in purchasing decisions,” said Devine.

Source: Invibio Biomaterial Solutions

published: November 17, 2017 in: Company News, Launches / Withdrawals, Regulatory, Technology

Leave a Reply

Your email address will not be published. Required fields are marked *

Most read

Latest

^